Effectiveness of an Intravenous Insulin–Based Treatment Protocol for the Management of Hypertriglyceridemia-Associated Acute Pancreatitis
Authors:
- 10 February 2023
- journal article
- research article
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 39 (2) , 55-61
Abstract
Background: There is burgeoning interest in intravenous insulin for hypertriglyceridemia-induced acute pancreatitis (HTG-AP) as a less invasive alternative to plasmapheresis; however, there are few published descriptions of disease-specific insulin protocols. Objective: To compare the efficacy and safety of an insulin infusion–based protocol with nonstandardized medical therapy for HTG-AP. Methods: This is a retrospective analysis before and after creation of an HTG-AP-specific insulin infusion treatment protocol. Inclusion criteria were age ≥18 years, an initial triglyceride level >1000 mg/dL, and a diagnosis of AP. The primary outcome of the study was time to a triglyceride level ≤1000 mg/dL. Results: Sixty-seven patients were included in this study (26 pre-protocol and 41 in the HTG-AP insulin protocol group). Baseline characteristics between the groups were similar, with median initial triglyceride levels >3500 mg/dL. There was a trend toward patients treated with the HTG-AP-specific infusion reaching a triglyceride level ≤1000 mg/dL faster (43.3 [24.9-72.1] vs 26.9 [17.7-51.1] hours; P = 0.07). Those treated to ≤500 mg/dL achieved this faster with the disease-specific infusion (49.2 [29.4-67.8] vs 70.9 [36.3-107.2] hours, P = 0.04). Hypoglycemia was numerically lower in the HTG-AP-specific insulin infusion group despite higher insulin infusion rates (7.3% vs 19.2%). No patient in the HTG-AP-specific protocol group required plasmapheresis. Conclusions: The use of an HTG-AP-specific insulin infusion protocol, compared with antecedent nonstandardized care, resulted in prompter achievement of a triglyceride level ≤500 mg/dL and a strong trend toward faster achievement of ≤1000 mg/dL without an increased risk of hypoglycemia. While intravenous insulin may be considered the initial medical therapy for HTG-AP, further studies are needed to determine the optimal dosing.Keywords
This publication has 19 references indexed in Scilit:
- Hypertriglyceridemic Pancreatitis Treated with Insulin Therapy: A Comparative Review of 34 CasesCureus, 2018
- The effect of intravenous insulin, apheresis and oral lipid-lowering agents on non-fasting hypertriglyceridemia and associated pancreatitisPostgraduate Medicine, 2018
- Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature reviewArchives of Endocrinology and Metabolism, 2017
- Acute PancreatitisNew England Journal of Medicine, 2016
- Current knowledge of hypertriglyceridemic pancreatitisEuropean Journal of Internal Medicine, 2014
- Plasma Exchange versus Intravenous Immunoglobulin for Myasthenia Gravis Crisis: An Acute Hospital Cost Comparison StudyJournal of Clinical Neuromuscular Disease, 2011
- Insulin and heparin in treatment of hypertriglyceridemia-induced pancreatitisWorld Journal of Gastroenterology, 2007
- Hypertriglyceridemia-induced pancreatitis: A case-based reviewWorld Journal of Gastroenterology, 2006
- Issues in Hyperlipidemic PancreatitisJournal of Clinical Gastroenterology, 2003
- Hyperlipidemic pancreatitis.1990